Vangelis G. Manolopoulos PhD

Professor of Pharmacology
Head of the Laboratory of Pharmacology
Faculty of Medicine, Democritus University, Greece
Download Full CV


Telephone3025510-30523 / Fax +3025510-30523
AddressLaboratory of Pharmacology,
Faculty of Medicine,
Democritus University of Thrace,
Dragana, Alexandroupolis,
68100, Greece.


  • Head of the Laboratory of Pharmacology, Faculty of Medicine, DUTH
  • Professor, Laboratory of Pharmacology, Medical School, Democritus University of Thrace, and Clinical Pharmacology and Pharmacogenetics Unit, Academic General Hospital of Evros, Alexandroupolis, Greece
  • 01/09 – 10/13 Associate Professor, as above
  • 01/03 - 12/08 Assistant Professor, as above
  • 12/98 - 01/03 Lecturer, as above
  • 09/95 - 11/98 Research Associate, Laboratory of Physiology, Medical School, Katholieke Universiteit Leuven, Belgium (Mentor: Prof Bernd Nilius)
  • 07/97 - 12/97 Researcher, Department of Biomedical Research, 251 Air Forces General Hospital, Athens, Greece
  • 01/92 - 08/95 Postdoctoral Fellow, Laboratory of Cell Biology, Department of Medicine, University of Wisconsin Medical School, Milwaukee, WI, USA (Mentor: Prof Peter I Lelkes)
  • 01/87 - 12/91 Research Assistant, Department of Pharmacology, University of Patras Medical School, Patras, Greece
  • 10/89 - 07/90 Visiting Scientist, Department of Clinical Pharmacology, University of Groningen Medical School, Groningen, The Netherlands
  • 01/85 - 12/86 Research Assistant, Experimental Embryology Laboratory, University of Patras, Greece



  • European Society for Pharmacogenomics and Personalized Therapy (ESPT): Vice President (2014-2016), founding Board Member, Chair of Education and Courses Division (2011- ).
  • Greek Society for Basic and Clinical Pharmacology (GSP): Vice President 2015-2017, constantly elected since 2003 on the Board in various positions (Treasurer 2003-2007, General Secretary 2007-2009 & 2013-2015)
  • Greek Atherosclerosis Society: Member (2007-2009) and Head (2009-2011) of the Steering Board of the Working Group on the Study of Pathophysiology of Atherosclerosis.
  • European Association of Clinical Pharmacology and Therapeutics (EACPT) Representative of Greek Pharmacological Society to the Board (2005-2007 and 2007-2011).


  • American Society for Pharmacology and Experimental Therapeutics (ASPET) since 1998
  • European Association of Clinical Pharmacology and Therapeutics (EACPT ) individual member (2015)
  • European Atherosclerosis Society (EAS) since 2011
  • Atherosclerosis Society of Northern Greee (EABE) Founding member (2006)
  • Greek Atherosclerosis Society (since 2003)


  • Ethics Board of Academic General Hospital of Evros: Member (2005-2009) και Head (2009-2015)
  • Scientific Council of Academic Hospital of Evros (2005-2015)
  • Drug Formulary Committee of Academic Hospital of Evros (2003-2011)
  • Narcotics Commitee of Academic Hospital of Evros (2003-2011)
  • Internal Evaluation Committee of the Democritus University of Thrace Medical School (2008-2009)


  • European Pharmacogenetics Implementation Consortium (Eu-PIC), Coordinator: Prof Ron van Schaik, Rotterdam, the Netherlands
  • Pharmacogenetics in Childhood Asthma Consortium (PICA), Coordinator: Prof Anke-Hilse Maitland van der Zee, Utrecht, the Netherlands
  • Clinical Pharmacogenetics Implementation Consortium (CPIC), USA-based guideline development platform of PharmGKB


  • Pharmacogenomics (since April 2011)
  • Drug Metabolism & Personalised Therapy (formerly Drug Metabolism & Drug Interactions (since Nov 2010)
  • Current Pharmacogenomics and Personalized Medicine (since Oct 2012)
  • Hellenic Journal of Athrosclerosis (since Sep 2010)

Research & Development


  • Clinical applications of pharmacogenomics in drugs for cardiovascular diseases, diabetes, anticoagulant therapy, childhood asthma, and psychiatric diseases.
  • Personalized medicine in cardiovascular and psychiatric field (including epigenetics and other omics)
  • Identification of novel genetic factors predisposing to atheromatosis, coronary artery disease, hypertension, diabetes, obesity, pediatric asthma, diabetic nephropathy, ischemic stroke.
  • Hydrogen Sulfide (H2S): (patho)physiological actions, heterogeneity of regulation.
  • Analysis of cardioprotective functions of natural compounds (pomegranate, asparagus officinalis)


  • Program THALIS / Greek Secretariat of Research and Technology: «Hydrogen Sulfide (H2S) a new endogenous regulator of angiogenesis: signaling, physiology/ patho-physiology and development of pharmacological inhibitors» (H2S Biology) / Total funding 521.000 € (80.000 € for my group) / co-investigator / 01/03/2012 – 30/09/2015.
  • FP7-2007-HEALTH European Integrated Program,: «European Pharmacogenomics of Anticoagulant Therapy» (EU- PACT) in thematic line «Collaborative project HEALTH-2007-2.4.2-7: Integrating pharmacogenomic approaches into the treatment of cardiovascular disease» / European Consortium (12 Labs / 7 countries) / Total EU fundind: 3.000.000 € (295.000 € for Greece) / I was member of the Steering Board, and the National Coordinator and Principal Investigator for Greece / 01/10/2008 – 31/03/2013.
  • Greek Atherosclerosis Society / Research Program: «Study on the factors associated with vessel calcification in patients with diabetic nephropathy» / 5.000 € / Principal Investigator of the program / 01/09/2011 – 31/08/2013.
  • Greek Health Ministry, Special Account of Research & Development of 4th Health Periphery / Research Program: «Genetic factors that govern the incidence of bronchial asthma in children and the therapeutic response of these patients to pharmacotherapy» / 12.000 € / Principal Investigator / 01/01/2010 – 31/12/2010.
  • Program TECHNOGENESIS / 2005-2006. Participated in Innovation Reinforcement Program “Technogenesis” of Region of Macedonia and Thrace with the proposal«Center of Genomic-Pharmacogenomic Health Services» that was evaluated in the 10 best proposals (among 300 submitted), received funding of 80.000 €, and was implemented with the foundation of a spin-off pharmacogenomic company.


  • 93 Publications in referenced international scientific journals
  • Book Chapters in Books, e-papers: 6
  • Η-index : 27
  • Total impact factor : 449.776
  • Citations : approx 2320

[Individual Impact Factors and citations are shown in every citation. IF* denotes journals that do not exist anymore, and the IF shown is the last available].


1. Ragia G, Dahl ML, Manolopoulos VG “Influence of CYP3A5*1 allele on the pharmacokinetics and clinical effects of psychiatric drug” Current Drug Metabolism, accepted (IF: 3.487)

2. Tavridou A, Georgoulidou A, Roumeliotis A, Roumeliotis S, Giannakopoulou E, Papanas N, Passadakis P, Manolopoulos VG, Vargemezis V, “Association of plasma adiponectin and oxidized low-density lipoprotein with carotid intima-media thickness in diabetic nephropathy” Journal of Diabetes Research 2015:507265, 2015. doi: 10.1155/2015/507265. (IF: 2.164, citations: 0)

3. Misailidis G, Ragia G, Ivanova DD, Tavridou A, Manolopoulos VG “Gene-gene interaction of µ-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect” Drug Metabolism and Personalised Therapy 30(2):129-35, 2015. (no IF, citations: 0)

4. Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH on behalf of the EU-PACT consortium “Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants” Thrombosis Research 136(1):69-75, 2015. (IF: 2.447, citations: 0)

5. Zhang Y,de Boer A,Verhoef TI,van der Meer FJ, Le Cessie S, Maitland-van der Zee AH ; EU-PACT group (Barallon R,de Boer A, Daly A,Redekop K, Stingl J,Manolopoulos VG,Rosendaal FR, Wadelius M) “Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands” Thrombosis Research 136(1):94-100, 2015. (IF: 2.447, citations: 0)

6. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, van Schaik RHN, Kolovou G, Manolopoulos VG, “ No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid­ lowering response to statins in Greek patients with primary hypercholesterolemia” Drug Metabolism and Personalised Therapy 30(1):43-48, 2015. (no IF, citations: 6)

7. Kolovou G, Kolovou V, Ragia G, Mihas C, Diakoumakou O, Vasiliadis I, Mavrogeni S, Vartela V, Manolopoulos VG “CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin” Genetics and Molecular Biology 38(2):129-137, 2015. (IF 2014: 1.202, citations: 2)

8. Drogari E, Ragia G, Mollaki V, Elens L, Van Schaik RHN, Manolopoulos VG, “The P450 oxidoreductase *28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia” Pharmacogenomics 15(16):1963-1972, 2014. (IF:3.218, citation:1)

9. Ragia G, Giannakopoulou E, Karatza ΙM, Karaglani M, Tavridou A, Manolopoulos VG “Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance” Drug Metabolism and Drug Interactions 29(4):235-248, 2014. (no IF, citations: 4)

10. Iordanidou M, Paraskakis E, Giannakopoulou E, Tavridou A, Gentile G, Borro M, Simmaco M, Chatzimichail A, Bush A, Manolopoulos VG, Vitamin D receptor ApaI a allele is associated with better childhood asthma control and improvement in ability for daily activities” OMICS: A Journal of Integrative Biology 18(11):673-681, 2014. (IF: 2.362, citations: 4)

11. Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis A, Elisaf M, Kolovou G, Manolopoulos VG, "No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population" Molecular Biology Reports 41:4631-4638, 2014 (IF:2.024, citations:6)

12. Knappskog S, Gansmo LB, Dibirova K, Metspalu A, Cybulski C, Peterlongo P, Aaltonen L, Vatten L, Romundstad P, Hveem K, Devilee P, Evans G, Lin D, van Camp G, Manolopoulos VG, Osorio A, Milani L, Ozcelik T, Zalloua P, Mouzaya F, Bliznetz E, Balanovska E, Pocheshkova E, Kucinskas V, Atramentova L, Nymadawa P, Titov K, Lavryashina M, Yusupov Y, Zamora J, Wedge DC, Charlesworth D, Dörk T, Balanovsky O and Lønning PE, “Population Distribution and Ancestry of the Cancer Protective MDM2 SNP285 (rs117039649)” Oncotarget 5(18):8223-8234, 2014. (IF: 6.359, citations: 1)

13. Kolovou G, Ragia G, Kolovou V, Mihas C, Katsiki N, Vasiliadis I, Mavrogeni S, Vartela V, Tavridou A, Manolopoulos VG "Impact of CYP3A5 gene polymorphism on efficacy of simvastatin" The Open Cardiovascular Medicine Journal 8:12-17, 2014. (no IF, citations: 5)

14. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis A, Elisaf M, van Schaik R, Kolovou G, Manolopoulos VG “Lack of association of the P450 oxidoreductase *28 SNP with the lipid lowering response to statins in hypercholesterolemic patients” Molecular Diagnosis & Therapy 18(3): 323-331, 2014. (IF: 2.891, citations: 8)

15. Ragia G, Elens L, Tavridou A, van Schaik R, Manolopoulos VG “CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas” Experimental and Clinical Endocrinology and Diabetes, 122:60-63, 2014. (IF: 1.555, citations: 6)

16. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJM, Redekop WK, Remkes M, Rosendaal FR, van Schie RMF, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH, on behalf of EU-PACT group “A randomised controlled trial to assess the added value of VKORC1 and CYP2C9 genotyping before start of acenocoumarol and phenprocoumon treatment” New England Journal of Medicine 369:2304-2312, 2013. (IF:55.873, citations: 90)

17. Pirmohamed M,Burnside G,Eriksson N,Jorgensen AL,Toh CH,Nicholson T,Kesteven P,Christersson C,Wahlström B,Stafberg C,Zhang JE,Leathart JB, Kohnke H, Maitland-van der Zee AH , Williamson PR,Daly AK,Avery P,Kamali F,Wadelius M;EU-PACT Group (Barallon R,de Boer A, Daly A,Haschke-Becher E,Kamali F,Maitland-van der Zee AH,Redekop K, Stingl J,Manolopoulos VG,Pirmohamed M,Rosendaal FR,Wadelius M). “A randomized trial of genotype-guided dosing of warfarin” New England Journal of Medicine 369(24):2294-2303, 2013. (IF: 55.873, citations: 95)

18. Alzahrani AM, Ragia G, Haneya H, Manolopoulos VG, “Genotyping of CYP2C9 and VKORC1 in the arabic population of Al-Ahsa, Saudi Arabia” BioMed Research International, vol. 2013, Article ID 315980, 2013. doi:10.1155/2013/315980. (IF: 1.579, citations: 4)

19. Ragia G, Iordanidou M, Giannakopoulou E, Tavridou A, Manolopoulos VG “Association of DRD2 Taq1A and DβH -1021C>T gene polymorphisms with smoking initiation and their interaction with serotonergic system gene polymorphisms” Current Pharmacogenomics and Personalized Medicine 11(2):110-117, 2013. (no IF, citations: 1)

20. Giannakopoulou E, Ragia G, Maroussi S, Elloul I, Manolopoulos VG, Tavridou A, “Association of monocyte chemoattractant protein-1 -2518A>G polymorphism with occurrence, severity, and outcome in ischemic stroke” Neurological Sciences 34(8):1315-1320, 2013. (IF: 1.447, citations: 3)

21. Verhoef TI,Redekop WK,Veenstra DL,Thariani R,Beltman PA,van Schie RM, de Boer A, Maitland-van der Zee AH ; EU-PACT Group (Barallon R,de Boer A, Daly A,Haschke-Becher E,Kamali F,Maitland-van der Zee AH,Redekop K, Stingl J,Manolopoulos VG,Pirmohamed M,Rosendaal FR, Wadelius M) “Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation”. Pharmacogenomics 14(8):869-883, 2013. (IF: 3.218, citations: 7)

22. Ragia G, Marousi S, Ellul J, Manolopoulos VG, Tavridou A “Association of functional VKORC1 promoter polymorphism with occurrence and clinical aspects of ischemic stroke in a Greek population” Disease Markers 35(6):641-646, 2013. (IF: 1.562, citations: 2)

23. Staikos C, Ververidis A, Drosos G, Manolopoulos VG, Verettas D-A, Tavridou A “The association of adipokine levels in plasma and synovial fluid with the severity of knee osteoarthritis” Rheumatology, 52(6):1077-1083, 2013. (IF: 4.475, citations: 32)

24. Ragia G, Tavridou A, Petridis I, Manolopoulos VG, “Association of KCNJ11 E23K gene polymorphism

with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients” Diabetes Research and Clinical Practice 98:119-124, 2012. (IF: 2.538, citations: 9)

25. Verhoef TI, Redekop WK, Van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin L-A, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH, on behalf of the EU-PACT group. “Cost-effectiveness of pharmacogenetics in anticoagulation; international differences in healthcare systems and costs” Pharmacogenomics 13(12):1405-1417, 2012. (IF: 3.218, citations: 7)

26. Iordanidou M, Paraskakis E, Tavridou A, Paschou P, Chatzimichail A, Manolopoulos VG, “G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting β2 agonists in asthmatic children” Pharmacogenomics 13(12):1363-1372, 2012. (IF: 3.218, citations: 8)

27. Donnelly MP, Paschou P, Grigorenko E, Gurwitz D, Barta C, Lu R-B, Zhukova OV, Kim J-J, Siniscalco M, New M, Li H, Kajuna S, Manolopoulos VG, Speed WC, Pakstis AJ, Kidd JR, Kidd KK “A global view of the OCA2-HERC2 region and pigmentation” Human Genetics 131(5):683-696, 2012. (IF: 4.824, citations: 32)

28. Verhoef TI,Redekop WK,Hegazy H, de Boer A, Maitland-van der Zee AH ; EU-PACT group (Barallon R,de Boer A, Daly A,Haschke-Becher E,Kamali F, Maitland AH,Redekop K, Stingl J,Manolopoulos VG,Pirmohamed M,Rosendaal FR, Wadelius M), “Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users” Journal of Thrombosis Haemostasis 10(12):2610-2612, 2012. (IF: 5.720, citations: 15)

29. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, Wessels JA, Van Schie RM, De Boer A, Teichert M, Visser LE, Maitland-Van Der Zee AH; EU-PACT Group. “Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users” Journal of Thrombosis Haemostasis 10(4):606-14, 2012. (IF: 5.720, citations: 15)

30. van Schie RM, Babajeff AM, Schalekamp T, Wessels JA, le Cessie S, de Boer A, van der Meer FJ, van Meegen E, Verhoef TI, Rosendaal FR, Maitland-van der Zee AH; EU-PACT study group. “An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol” Journal of Thrombosis Haemostasis 10(5):767-72, 2012. (IF: 5.720, citations: 6)

31. Stathias V, Sotiris GR, Karagiannidis I, Bourikas G, Martinis G, Papazoglou D, Tavridou A, Papanas N, Maltezos E, Theodoridis M, Vargemezis V, Manolopoulos VG, Speed WC, Kidd JR, Kidd KK, Drineas P, Paschou P “Exploring genomic structure differences and similarities between the Greek and European HapMap populations; implications for association studies” Annals of Human Genetics 76(6):472-483, 2012. (IF: 2.211, citations: 5)

32. Avery PJ, Jorgensen A, Hamberg AK,Wadelius M,Pirmohamed M,Kamali F;EU-PACT Study Group (de Boer A, Daly AK, Haschke-Becher E,Maitland-van der Zee AH,Manolopoulos VG,RedekopWK, Rosendaal FR, Stingl J). A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clinical Pharmacology and Therapeutics 90(5):701-706, 2011. (IF: 7.903, citations: 46)

33. Tavridou A, Petridis I, Vasiliadis M, Ragia G, Heliopoulos I, Vargemezis V, Manolopoulos VG “Association of VKORC1 -1639 G>A polymorphism with intima-media thickness in type 2 diabetes mellitus” Diabetes Research and Clinical Practice 94:236-241, 2011. (IF: 2.538, citations: 7)

34. van Schie RM, Wessels JA, le Cessie S,de Boer A,Schalekamp T,van der Meer FJ,Verhoef TI,vanMeegen E, de Boer A, Daly AK,Haschke-Becher E,Kamali F,Manolopoulos VG,Pirmohamed M,Redekop WK, Rosendaal FR, Stingl J,Wadelius M, Maitland-van der Zee AH. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. European Heart Journal 32(15):1909-17, 2011. (IF: 15.203, citations: 59)

35. Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis G, Bougioukas G, Manolopoulos VG. Endothelial nitric oxide synthase gene polymorphisms -786T>C and 894G>T in coronary artery bypass graft surgery patients” Human Genomics 4(6):1-9, 2010. (no IF, citations: 13)

36. Tavridou A, Efthimiadis A, Efthimiadis I, Manolopoulos VG. “Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia” Heart & Vessels 25(4):288-293, 2010. (IF: 2.065, citations: 19)

37. Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee A-H, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RMF, Wadelius M. “A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives” Pharmacogenomics 11(7): 989-1002, 2010. (IF: 3.218, citations: 17)

38. Iordanidou M, Tavridou A, Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, Manolopoulos VG “The serotonin transporter promoter polymorphism ( 5-HTTLPR) is associated with type 2 diabetes” Clinica Chimica Acta 411:167-171, 2010. (IF: 2.824, citations: 33)

39. Iordanidou M, Tavridou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, Manolopoulos VG “Association of polymorphisms of the serotoninergic system with smoking initiation in Caucasians”, Drug and Alcohol Dependence 108:70-76, 2010. (IF: 3.423, citations: 18)

40. Donnelly MP, Paschou P, Grigorenko E, Gurwitz D, Mehdi SO, Kajuna SLB, Barta C, Kungulilo S, Karoma NJ, Lu R-Β, Zhukova OV, Kim J-J, Comas D, Siniscalco M, New M, Li P, Li H, Manolopoulos VG, Speed WC, Rajeevan H, Pakstis AJ, Kidd JR, Kidd KK. “The Distribution and Most Recent Common Ancestor of the 17q21 Inversion in Humans”,. American Journal of Human Genetics 86(2):161-171, 2010. (IF: 10.931, citations: 28)

41. Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis G, Bougioukas G, Manolopoulos VG “Renin-angiotensin system gene polymorphisms in coronary artery bypass graft surgery patients” Journal of Renin Angiotensin Aldosterone System 11(2):136-145, 2010 (IF:2.400, citations:9)

42. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG, " Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: The case of Greece" Pharmacogenomics 10: 43-49, 2009. (IF: 3.218, citations: 47)

43. Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H “Oxidized low-density lipoprotein and arterial function in beta- thalassemia major” European Journal of Haematology 82: 477-483, 2009. (IF: 2.066, citations: 11)

44. Tavridou A, Arvanitidis KI, Tiptiri-Kourpeti A, Petridis J, Ragia G, Kyroglou S, Christakidis D, Manolopoulos VG " Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population” Diabetes Research and Clinical Practice 84(2): 132- 137, 2009. (IF: 2.538, citations: 11)

45. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG, “Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulphonylurea oral hypoglycemic agents” Pharmacogenomics 10: 1781-1787, 2009. (IF: 3.218, citations: 42)

46. Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka E, Kourounakis PN, Charalambus A, Manolopoulos VG, "Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit" Journal of Cardiovascular Pharmacology 51(6):573-580, 2008. (IF: 2.111, citations: 9)

47. Iordanidou M, Tavridou A, Vasiliadis MV, Arvanitidis KI, Petridis J, Christakidis DA, Vargemezis V, Bougioukas G, Manolopoulos VG, “The -759 C/T polymorphism of the 5-HT2C receptor is associated with type II diabetes in male and female Caucasians” Pharmacogenetics & Genomics, 18 (2):153-159, 2008. (IF: 3.481, citations: 11)

48. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG. “Genetic polymorphisms of drug-metabolising enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population”. Fundamental and Clinical Pharmacology, 21 (4): 419-426, 2007. (IF: 2.121, citations: 71)

49. Tavridou A, Megaritis G, Kourounakis AP, Charalambous A, Manolopoulos VG, "EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate eNOS expression in cultured endothelial cells" Endothelium, 14 (4): 239-243, 2007. (IF*: 1.929, citations: 16)

50. Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG, “EP2306, a novel squalene synthase inhibitor, inhibits atherosclerosis in the cholesterol-fed rabbit”. Journal of Pharmacology Experimental Therapeutics, 323(3): 794-804, 2007. (IF: 3.972, citations: 15)

51. Tavridou A, Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka E, Kourounakis PN, Charalambous A, Manolopoulos VG, "Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and atherosclerosis". European Journal of Pharmacology, 535: 34-42, 2006. (IF: 2.532, citations: 39)

52. Tentes AAK, Markakidis SK, Karanikiotis C, Fiska A, Tentes AK, Manolopoulos VG, Dimitriou T, “Intra-arterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer”. Langenbeck’s Archives of Surgery, 391: 124-129, 2006. (IF: 2.191, citations: 4)

53. Tavridou A, Manolopoulos VG, "Atorvastatin and simvastatin decrease the uptake of acetylated-low density lipoprotein by hyman monocytes”, Pharmacology 73: 102-105, 2005. (IF: 1.672, citations: 3)

54. Tavridou A, Manolopoulos VG, "Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivoEuropean Journal of Pharmacology 505: 213-221, 2004. (IF: 2.532, citations: 23)

55. Papadimitriou E, Waters CR, Manolopoulos VG, Unsworth BR, Maragoudakis ME, Lelkes PI, “Regulation of extracellular matrix remodeling and MMP-2 activation in cultured rat adrenal medullary endothelial cells”, Endothelium 8: 181-194, 2001. (I.F*: 1.929, citations: 11)

56. Manolopoulos VG, Liekens S, Koolwijk P, Voets T, Peters E, Droogmans G, Lelkes PI, De Clercq E, Nilius B, “Inhibition of angiogenesis by blockers of volume-regulated anion channels”, General Pharmacology 34: 107-116, 2000. (I.F*: 1.986, citations: 44)

57. Suh SH, Vennekens R, Manolopoulos VG, Freichel M, Schweig U, Prenen J, Flockerzi V, Droogmans G, Nilius B, “Characterization of explanted endothelial cells from mouse aorta: electrophysiology and Ca2+- signalling”, Pflügers Archiv European Journal of Physiology 438:612-20, 1999 (IF:4.101, citations: 67)

58. Mountian I, Manolopoulos VG, De Smedt H, Parys JB, Missiaen L, Wuytack F, “Expression patterns of sarco/endoplasmatic reticulum Ca2+-ATPase and inositol 1,4,5-trisphosphate receptor isoforms in vascular endothelial cells”, Cell Calcium 25: 371-380, 1999. (IF: 3.513, citations: 58)

59. Voets T, Manolopoulos V, Eggermont J, Ellory C, Droogmans G, Nilius B, “Regulation of swelling- activated chloride current in bovine endothelium by protein tyrosine phosphorylation and G proteins”, Journal of Physiology (London) 506: 341-352, 1998. (IF: 5.139, citations: 145)

60. Manolopoulos VG, Fenton II JW, Lelkes PI, "The thrombin receptor in adrenal medullary endothelial cells is negatively coupled to adenylyl cyclase through a Gi-protein" Biochimica Biophysica Acta 1356: 321- 332, 1997. (IF: 4.381, citations: 23)

61. Papadimitriou E, Manolopoulos VG, Hayman GT, Maragoudakis ME, Unsworth BR, Fenton JW, Lelkes PI, “Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells”, American Journal of Physiology (Cell Physiology) 272: C1112-C1122, 1997. (IF: 3.780, citations: 48)

62. Manolopoulos VG, Voets T, Declercq PE, Droogmans G, Nilius B,“Swelling-activated efflux of taurine and other organic osmolytes in endothelial cells”, American Journal of Physiology (Cell Physiology) 273: C214-C222, 1997. (IF: 3.780, citations: 42)

63. Manolopoulos VG, Droogmans G, Nilius B, “Hypotonicity and thrombin activate taurine efflux in BC3H1 and C2C12 myoblasts that is down regulated during differentiation”, Biochemical Biophysical Research Communications 232: 74-79, 1997. (IF: 2.297, citations: 26)

64. Manolopoulos VG, Prenen J, Droogmans G, Nilius B, “Thrombin potentiates volume-activated chloride currents in pulmonary artery endothelial cells” Pflügers Archiv European Journal of Physiology 433: 845-847, 1997. (IF: 4.101, citations: 19)

65. Silverman MD, Manolopoulos VG, Unsworth BR, Lelkes PI, "Tissue factor expression is differentially modulated by cyclic mechanical strain in various human endothelial cells", Blood, Coagulation, and Fibrinolysis 7: 281-288, 1996. (IF: 1.403, citations: 24)

66. Efthimiopoulos S, Punj S, Manolopoulos V, Pangalos M, Wang GP, Refolo LM, Robakis NK, "Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein", Journal of Neurochemistry 67: 872-875, 1996. (IF: 4.281, citations: 55)

67. Manolopoulos VG, Samet MM, Lelkes PI, "Regulation of the adenylyl cyclase signaling system in various types of cultured endothelial cells", Journal of Cellular Biochemistry 57:590-598, 1995. (IF: 3.263, citations: 34)

68. Manolopoulos VG, Liu J, Unsworth BR, Lelkes PI, "Adenylyl cyclase isoforms are differentially expressed in primary cultures of endothelial cells and whole tissue homogenates from various rat tissues", Biochemical Biophysical Research Communications 208: 323-331, 1995 (IF 2014: 2.297, citations: 45)

69. Manolopoulos VG, Lelkes PI, "Cyclic strain and forskolin differentially induce cAMP production in phenotypically diverse endothelial cells", Biochemical Biophysical Research Communications 191: 1379-85, 1993. (IF: 2.297, citations: 34)

70. Manolopoulos VG, Pipili-Synetos E, den Hertog A, Nelemans A, "Inositol phosphates formed in rat aorta after a1-adrenergic stimulation are inhibited by forskolin", European Journal of Pharmacology 207: 29- 36, 1991. (IF: 2.532, citations: 26)

71. Synetos D, Manolopoulos VG, Atlas D, Pipili-Synetos E, "A human plasma-derived material with clonidine displacing substance (CDS)-like properties, contracts the isolated rat aorta", Journal of Autonomic Pharmacology 11: 343-351, 1991. (I.F*: 1.825, citations: 22)

72. Pipili E, Manolopoulos VG, Catravas JD, Maragoudakis ME, "Angiotensin converting enzyme activity is present in the endothelium-denuded aorta", British Journal of Pharmacology 98: 333-335, 1989. (IF: 4.842, citations: 40)


1. Ragia G, Dahl ML Manolopoulos VG “CYP3A5 genetic polymorphism: is it important for psychiatric drugs?” Current Drug Metabolism, submitted

2. Belley-Cote EP, Hanif H, D’Aragon F, Eikelboom JW, AndersonJL, Borgman M, Jonas DE, Kimmel SE, Manolopoulos VG, Baranova E, Maitland-van der Zee AH, Pirmohamed M, Whitlock RP “Genotype-Guided Versus Standard Vitamin K Antagonist Dosing Algorithms in Patients Initiating Anticoagulation: A Systematic Review and Meta-Analysis” Thrombosis Haemostasis 114(3): 2015. (IF: 4.984, citations: 0)

3. Ragia G, Manolopoulos VG “Pharmacogenomics of Alcohol Addiction: Personalizing Pharmacologic Treatment of Alcohol Dependence” Hospital Pharmacology 1(3):147-167, 2014. (no IF, citations: 1)

4. Hekim N, 28 authors, Manolopoulos VG, 12 authors, Özdemir V, “Translating Biotechnology to Knowledge-based Innovation, Peace and Development? Deploy a Science Peace Corps -- An Open Letter to World Leaders” OMICS: A Journal of Integrative Biology 18(7):415-420, 2014. (IF: 2.362, citations: 2)

5. Maitland-van der Zee AH, de Boer A, Manolopoulos VG; EU-PACT Group. “Genotype-guided dosing of vitamin K antagonists”. New England Journal of Medicine 370(18):1765-1766, 2014. (IF: 55.873, citations: 1)

6. Maitland-van der Zee AH, Daly AK, Kamali F, Manolopoulos VG, Verhoef TI, Wadelius M, de Boer A, Pirmohamed M on behalf of the EU-PACT study group Patients benefit from genetics-guided warfarin therapy” Clinical Pharmacology and Therapeutics 96:15-17, 2014. (IF: 7.903, citations: 0)

7. Özdemir V, Borda-Rodriguez A, Dove ES, Ferguson LR, Huzair F, Manolopoulos VG, Masellis M, Milius D, Warnich L, Srivastava S, “Public Health Pharmacogenomics and the Design Principles for Global Public Goods – Moving Genomics to Responsible Innovation Current Pharmacogenomics and Personalized Medicine 11(1):1-4, 2013. (no IF, citations: 5)

8. Ragia G, Manolopoulos VG “Research highlights” Pharmacogenomics 13(3):261-264, 2012. (IF:3.218, citations: 0)

9. Manolopoulos VG , Ragia G, Alevizopoulos G, “Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics” Drug Metabolism and Drug Interactions 27(1):19-31, 2012. (no IF, citations: 6)

10. Manolopoulos VG, Ragia G, Tavridou A “Pharmacogenomics of oral antidiabetic treatment: current data and pharmacoepigenomic perspective” Pharmacogenomics 12(8):1161-1191,2011 (IF:3.218,citations:31)

11. Manolopoulos VG, Dechairo B, Huriez A, Kuehn A, Llerena A, Van Schaik R, Yeo J, Ragia G, Siest G, “Fifth Santorini conference pharmacogenomics roundtable report: Pharmacogenomics and personalized medicine in clinical practice” Pharmacogenomics 12(5):681-691, 2011. (IF: 3.218, citations: 10)

12. Tavridou A, Ragia G, Manolopoulos VG “Emerging targets for the treatment of dyslipidemia” Current Medicinal Chemistry 18(6):909-922, 2011. (IF: 3.853, citations: 17)

13. Squassina A, Artac M, Manolopoulos VG, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Manchia M, Del Zompο Μ, Patrinos GP. “Translation of genetic knowledge into clinical practice: the expectations and realities of pharmacogenomics and personalized medicine” Pharmacogenomics 11(8):1149-1167, 2010. (IF: 3.218, citations: 3)

14. Manolopoulos VG, Ragia G, Tavridou A “Pharmacogenetics of Coumarinic Oral Anticοagulants” Pharmacogenomics 11(4): 493-496, 2010. (IF: 3.218, citations: 44)

15. Tavridou A, Manolopoulos VG, EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors” Current Pharmaceutical Design 15(27): 3167-3178, 2009. (IF: 3.452, citations: 9)

16. Manolopoulos VG, Tavridou A, “Drugs targeting atherosclerosis: current and emerging approaches” Current Pharmaceutical Design 15(27):3091-3093, 2009. (IF: 3.452, citations: 1)

17. Tavridou A, Manolopoulos VG, “Inhibitors of 5-lipoxygenase activating protein (FLAP) – WO20080-30369” E xpert Opinion on Therapeutic Patents, 19(10): 1473-1476, 2009. (IF: 4.297, citations: 1)

18. van Schie RMF, Wadelius M, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland- van der Zee A-H, “Genotype-guided dosing of coumarin derivatives: the European pharmacogenomics of anticoagulant therapy (EU-PACT) trial design” Pharmacogenomics 10: 1287-1295, 2009. (IF: 3.218, citations: 95)

19. Tavridou A, Manolopoulos VG. “Novel molecules targeting dyslipidemia and atherosclerosis” Current Medicinal Chemistry 15 (8): 792-802, 2008. (IF: 3.853, citations: 24)

20. A Llerena, G Michel, E Jeannesson, S Wong, VG Manolopoulos, et al. “Third Santorini conference pharmacogenomics workshop report: Pharmacogenomics at the crossroads: What else than good science will be needed for the field to become part of personalized medicine?”. Clinical Chemistry and Laboratory Medicine, 45: 843-850, 2007. (IF: 2.707, citations: 5)

21. VG Manolopoulos. “Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice”. Clinical Chemistry and Laboratory Medicine, 45: 801-814, 2007. (I.F. 2014: 2.707, citations: 27)

22. D Gurwitz, Lunshof J, G Dedoussis, CS Flordellis, U Fuhr, J Kirchheiner, J Licinio, A Llerena, VG Manolopoulos, LJ Sheffield, G Siest, F Torricelli, V Vasiliou, S Wong. “Pharmacogenomics education: International society of pharmacogenomics recommendations for medical, pharmaceutical and health schools deans of education” Pharmacogenomics Journal, 5: 221-225, 2005. (IF: 4.229, citations: 81)

23. B Nilius, J Eggermont, T Voets, G Buyse, V Manolopoulos, G Droogmans, “Properties of volume- regulated anion channels in mammalian cells”, Progress in Biophysics and Molecular Biology 68: 69- 119, 1997. (IF: 2.274, citations: 286)

© Page maintained by George Kolios; last updated: 09/2015